Harpoon_logo (002).jpg
Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023
March 14, 2023 18:21 ET | Harpoon Therapeutics
Preclinical abstracts for investigational T cell engagers, HPN328 and HPN217, in mouse models provide further validation of Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®)...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022
December 05, 2022 07:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon_logo (002).jpg
Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
November 14, 2022 16:01 ET | Harpoon Therapeutics
HPN217 (BCMA) interim data update at ASH 2022; HPN328 (DLL3) exploring dosing regimens and HPN601 (EpCAM) expected to enter the clinic in 2023 Strategic realignment to focus resources on ongoing...
Harpoon_logo (002).jpg
Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 10, 2022 16:01 ET | Harpoon Therapeutics
Presented encouraging interim data for anti-DLL3 T cell engager HPN328 from ongoing dose escalation clinical trial at the 2022 ASCO Annual Meeting Portfolio prioritization and resource alignment...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
August 02, 2022 07:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon_logo (002).jpg
Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217
March 02, 2022 07:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon_logo (002).jpg
Harpoon Therapeutics Provides Pipeline Development Milestones for 2022
January 11, 2022 08:00 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today provided a...
Harpoon_logo (002).jpg
Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms   
December 13, 2021 16:05 ET | Harpoon Therapeutics
Compelling initial clinical activity for HPN328 (DLL3) and HPN217 (BCMA) targeting programs observed in escalation phase of ongoing trialsEncouraging profile of tolerability and activity seen at...
Harpoon_logo (002).jpg
Harpoon Therapeutics Presents Interim Clinical Data from its Ongoing Phase 1/2 Study and New Preclinical Results for BCMA-targeting TriTAC® HPN217 at the 63rd ASH Annual Meeting and Exposition
December 11, 2021 09:00 ET | Harpoon Therapeutics
Encouraging clinical activity in higher dose cohorts with 63% ORR and 88% DCR reported in 2150 µg/week cohort with 8 disease evaluable patients with relapsed/refractory multiple myeloma Tolerable...
Harpoon_logo (002).jpg
Harpoon Therapeutics to Present at the 63rd ASH Annual Meeting and Exposition
November 04, 2021 09:00 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...